Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 2111–2119 | Cite as

ARNT2 is downregulated and serves as a potential tumor suppressor gene in non-small cell lung cancer

  • Bo Yang
  • Ende Yang
  • Hehe Liao
  • Zhouquan Wang
  • Zhiping Den
  • Hong Ren
Research Article

Abstract

The present study aims to investigate the expression pattern of aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) protein and its clinical significance in human non-small cell lung cancer (NSCLC). We investigated the expression levels of ARNT2 in 104 NSCLC surgical specimens by immunohistochemistry and then analyzed its clinical significance. Additionally, the role of ARNT2 on the biological properties of the NSCLC line HCC827 was experimentally tested in vitro and in vivo to confirm the clinical observations. We found that the expression level of ARNT2 was significantly higher in normal lung tissues compared with NSCLC tissues (P < 0.01). Overall survival (OS) of patients with a high intratumoral ARNT2 level was significantly longer than survival of those with a low ARNT2 level (P = 0.004). In addition, intratumoral ARNT2 expression was an independent prognostic factors for OS (hazard ratio [HR] = 0.529; P = 0.001). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that the ARNT2 overexpression inhibited cell viability, while ARNT2 knockdown promoted cell growth in NSCLC cell lines HCC827 and A549. Annexin V/PI assay showed that ARNT2 overexpression increased cell apoptosis, while ARNT2 knockdown decreased cell apoptosis in HCC827 and A549 cells. Moreover, in vivo study showed that attenuated ARNT2 expression in HCC827 cells greatly promoted tumor growth, while overexpressed ARNT2 remarkably inhibited tumor growth in a HCC827 xenograft model. Taken together, our data demonstrate that ARNT2 might serve as a tumor suppressor in NSCLC progression.

Keywords

ARNT2 Non-small cell lung cancer Tumor suppressor Proliferation Apoptosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.CrossRefPubMedGoogle Scholar
  2. 2.
    Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;vii Suppl 7:56–64. doi: 10.1093/annonc/mds226.Google Scholar
  3. 3.
    Li H, Zhang Y, Bai X, Peng Y, He P. TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor. Tumour Biol. 2014;35(6):5747–52. doi: 10.1007/s13277-014-1763-x.CrossRefPubMedGoogle Scholar
  4. 4.
    Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLH-PAS proteins in cancer. Nat Rev Cancer. 2013;13(12):827–41. doi: 10.1038/nrc3621.CrossRefPubMedGoogle Scholar
  5. 5.
    Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, et al. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol. 1996;16(4):1706–13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 1992;256(5060):1193–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Shi S, Yoon DY, Hodge-Bell KC, Bebenek IG, Whitekus MJ, Zhang R, et al. The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene. Carcinogenesis. 2009;30(11):1957–61. doi: 10.1093/carcin/bgp201.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res. 2002;8(2):471–80.PubMedGoogle Scholar
  9. 9.
    Liang Y, Li WW, Yang BW, Tao ZH, Sun HC, Wang L, et al. Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma. Int J Cancer. 2012;130(8):1745–54. doi: 10.1002/ijc.26166.CrossRefPubMedGoogle Scholar
  10. 10.
    Aitola MH, Pelto-Huikko MT. Expression of Arnt and Arnt2 mRNA in developing murine tissues. J Histochem Cytochem. 2003;51(1):41–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Hankinson O. Why does ARNT2 behave differently from ARNT? Toxicol Sci. 2008;103(1):1–3. doi: 10.1093/toxsci/kfn032.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Martinez V, Kennedy S, Doolan P, Gammell P, Joyce H, Kenny E, et al. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Res Treat. 2008;110(3):521–30. doi: 10.1007/s10549-007-9739-9.CrossRefPubMedGoogle Scholar
  13. 13.
    Qin XY, Wei F, Yoshinaga J, Yonemoto J, Tanokura M, Sone H. siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells. FEBS Lett. 2011;585(20):3310–5. doi: 10.1016/j.febslet.2011.09.017.CrossRefPubMedGoogle Scholar
  14. 14.
    Sribudiani Y, Metzger M, Osinga J, Rey A, Burns AJ, Thapar N, et al. Variants in RET associated with Hirschsprung’s disease affect binding of transcription factors and gene expression. Gastroenterology. 2011;140(2):572–82.e2. doi: 10.1053/j.gastro.2010.10.044.CrossRefPubMedGoogle Scholar
  15. 15.
    Sekine H, Mimura J, Yamamoto M, Fujii-Kuriyama Y. Unique and overlapping transcriptional roles of arylhydrocarbon receptor nuclear translocator (Arnt) and Arnt2 in xenobiotic and hypoxic responses. J Biol Chem. 2006;281(49):37507–16. doi: 10.1074/jbc.M606910200.CrossRefPubMedGoogle Scholar
  16. 16.
    Dougherty EJ, Pollenz RS. Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. Toxicol Sci. 2008;103(1):191–206. doi: 10.1093/toxsci/kfm300.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Bo Yang
    • 1
    • 3
  • Ende Yang
    • 2
  • Hehe Liao
    • 1
  • Zhouquan Wang
    • 1
  • Zhiping Den
    • 1
  • Hong Ren
    • 1
  1. 1.Second Department of Thoracic Surgery, The First Affiliated Hospital of Health Science CenterXi’an Jiao Tong UniversityXi’anChina
  2. 2.Department of Thoracic Surgery, Tangdu Hospitalthe Fourth Military Medical UniversityXi’anChina
  3. 3.Department of Thoracic SurgeryThe Fourth Hospital of Xi’anXi’anChina

Personalised recommendations